Skip to content

Clinical Double-Blind Randomized Controlled Trial of Quji Tongluo Decoction in Intervention of Branch Retinal Vein Occlusion Secondary Macular Edema

Clinical Double-Blind Randomized Controlled Trial of Quji Tongluo Decoction in Intervention of Branch Retinal Vein Occlusion Secondary Macular Edema

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003673
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-08-21
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Sponsors

Eye Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Between 40 and 70 years old; 2. It conforms to the Western medicine diagnostic criteria of non-ischemic branch retinal vein occlusion and conforms to the TCM syndrome differentiation criteria of phlegm and blood stasis. The course of the disease is more than 2 weeks; 3. OCT examination showed macular edema, and the thickness of the central retina was more than 250µm; 4. Agree to participate in this clinical trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. There is severe turbidity of the refractive medium; 2. Those with loss of central vision in the late course of the disease; 3. Combined with other macular diseases of the retina; 4. Persons who are allergic or possibly allergic to drugs; 5. Patients suffering from severe cardiovascular and cerebrovascular diseases or severely impaired liver and kidney function and systemic failure, or combined with severe global diseases, cannot tolerate relevant eye examinations and surgical treatment; 6. Women during pregnancy and lactation; 7. Patients who are participating in clinical trials of other drugs or who have used similar Chinese medicines and other treatments.

Design outcomes

Primary

MeasureTime frame
visual function;

Secondary

MeasureTime frame
TCM syndrome score;Recurrence time of macular edem;OCT measures macular edema;Vision-related quality of life in patients with macular edema secondary to branch retinal vein occlusion Questionnaire (The BRVO ME on Quality of Life (BMIQ) Questionnaire);The number of anti-VEGF drugs injected by the patient;FA detection of blood vessels in fundus;Patient's blood lipids (total cholesterol, triglycerides, high-density lipoprotein, low-density fat);

Countries

China

Contacts

Public ContactXie Like

Eye Hospital, China Academy of Chinese Medical Sciences

bjxielike@sina.com+86 13466782818

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026